20/20 Biolabs, Inc. Common Stock Total Liabilities
20/20 Biolabs, Inc. Common Stock total liabilities. Based on the latest financial reports, 20/20 Biolabs, Inc. Common Stock (AIDX) has total liabilities worth $3.13 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of 20/20 Biolabs, Inc. Common Stock to evaluate the company's liquid asset resilience ratio.
Total Liabilities of 20/20 Biolabs, Inc. Common Stock (2016–2024)
Total liabilities of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024. This chart illustrates how 20/20 Biolabs, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
20/20 Biolabs, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of 20/20 Biolabs, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UMT United Mobility Technology AG
XETRA:UMD
|
Germany | €3.32 Million |
|
Henry Boot PLC
LSE:BOOT
|
UK | GBX208.79 Million |
|
Bioatla Inc
NASDAQ:BCAB
|
USA | $45.88 Million |
|
Smiths News PLC
LSE:SNWS
|
UK | GBX164.50 Million |
|
Geekco Technologies Corp
V:GKO
|
Canada | CA$2.55 Million |
|
Rocky Mountain Liquor Inc
V:RUM
|
Canada | CA$12.40 Million |
|
Iveda Solutions Inc
NASDAQ:IVDA
|
USA | $1.65 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down 20/20 Biolabs, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AIDX asset base.
Liquidity & Leverage Metrics
20/20 Biolabs, Inc. Common Stock Total Liabilities Ratios Explained
20/20 Biolabs, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 28.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 20/20 Biolabs, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 20/20 Biolabs, Inc. Common Stock (2016–2024)
The table below shows the annual total liabilities of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.08 Million | -0.07% |
| 2023-12-31 | $2.08 Million | -26.77% |
| 2022-12-31 | $2.84 Million | -16.02% |
| 2021-12-31 | $3.38 Million | +162.58% |
| 2020-12-31 | $1.29 Million | +31.91% |
| 2019-12-31 | $976.56K | +19.01% |
| 2018-12-31 | $820.54K | -15.05% |
| 2017-12-31 | $965.94K | +71.89% |
| 2016-12-31 | $561.95K | -- |
About 20/20 Biolabs, Inc. Common Stock
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (… Read more